Use of antiplatelet and anticoagulant medicines in patients following thromboembolic stroke

Use of antiplatelet and anticoagulant medicines in patients following thromboembolic stroke | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 6 March 2026 V1 Latest version Share on Use of antiplatelet and anticoagulant medicines in patients following thromboembolic stroke Authors : Lorna Pairman 0000-0002-2436-4277 , Michael Falster 0000-0001-6444-7272 , Valerie Fletcher , John Fink , Paul Chin 0000-0002-5470-5191 , and Matthew Doogue [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.177277517.77030612/v1 143 views 80 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Aim To examine use of antiplatelet and anticoagulant medicines for two years following thromboembolic stroke. Methods Hospital and community medicines data for adult patients with a primary diagnosis of thromboembolic stroke between 01/01/2017 and 31/12/2021 in Canterbury, New Zealand, were linked with demographic, morbidity, and outcome data. Anticoagulant use was described for patients with atrial fibrillation or prior anticoagulant therapy (group B). Antiplatelet use was described for the remaining patients (group A). Variables associated with initiation of and persistence with treatment were identified. Results In group A (1,922 patients) 78% were dispensed an antiplatelet after discharge. In group B (1,072 patients) 66% were dispensed an anticoagulant after discharge. Reduced dispensing of both antiplatelets and anticoagulants after discharge was associated with prior haemorrhage and discharge into supported care (group A adjusted odds ratios [aOR] 0.4, 95% CI 0.3-0.7, and aOR 0.4, 0.3-0.6 respectively, and group B aOR 0.6, 0.4-0.8, and aOR 0.5, 0.3-0.7 respectively). Of those dispensed treatment following discharge, 49% persisted on antiplatelet treatment and 53% persisted on anticoagulant treatment until censored. Persistence on antiplatelet treatment was greater with polypharmacy (adjusted hazard ratio [aHR] 1.6, 1.4-1.9) and persistence on anticoagulation treatment reduced with higher deprivation (aHR 0.7, 0.5-0.9). Conclusion Real-world use of antiplatelet and anticoagulant treatment following thromboembolic stroke was suboptimal when compared to guidelines. There are opportunities to improve this, particularly in managing discharge medicines and medicines prescribed at the first community visit. Supplementary Material File (manuscript_unlinked_references.docx) Download 97.26 KB Information & Authors Information Version history V1 Version 1 06 March 2026 Copyright This work is licensed under a Non Exclusive No Reuse License. Authors Affiliations Lorna Pairman 0000-0002-2436-4277 University of Otago Christchurch View all articles by this author Michael Falster 0000-0001-6444-7272 University of New South Wales View all articles by this author Valerie Fletcher Health New Zealand Canterbury View all articles by this author John Fink Health New Zealand Canterbury View all articles by this author Paul Chin 0000-0002-5470-5191 University of Otago Christchurch View all articles by this author Matthew Doogue [email protected] University of Otago Christchurch View all articles by this author Metrics & Citations Metrics Article Usage 143 views 80 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Lorna Pairman, Michael Falster, Valerie Fletcher, et al. Use of antiplatelet and anticoagulant medicines in patients following thromboembolic stroke. Authorea . 06 March 2026. DOI: https://doi.org/10.22541/au.177277517.77030612/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.177277517.77030612/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9fe38793f9128e2e',t:'MTc3OTE5ODE5NQ=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();